An individual capital investment plan to construct a biologics drug substance manufacturing building and install manufacturing equipment at Kyowa Kirin’s Takasaki Plant. The total investment is ¥16.76 billion, with completion scheduled for March 2025, to establish production capacity for biologics drug substances.